• $48,275.00
    Market Cap
  • -60.00%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Income Statement
Total Operating Revenue
N/A
N/A
227
-96.33%
6,180
+236.78%
1,835
N/A
Cost of Revenue
N/A
N/A
91
-98.09%
4,768
+201.77%
1,580
N/A
Gross Profit
0
-100.00%
137
-90.30%
1,412
+453.73%
255
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
30,173
-64.95%
86,086
-42.63%
150,050
+72.89%
86,788
N/A
Operating Profit
-30,173
-64.89%
-85,950
-42.17%
-148,638
+71.77%
-86,533
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Income before Taxes
-30,173
-64.89%
-85,950
-42.17%
-148,638
+71.77%
-86,533
N/A
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
338,236
+493.53%
-85,950
-42.17%
-148,638
+71.77%
-86,533
N/A
Net Income from Continuing Operations Applicable to Common
338,236
+493.53%
-85,950
-42.17%
-148,638
+71.77%
-86,533
N/A
Basic EPS and Net Income
N/A
N/A
0.00
N/A
0.00
N/A
N/A
N/A
Diluted EPS and Net Income
N/A
N/A
0.00
N/A
0.00
N/A
N/A
N/A
Basic Weighted Average Shares
241.8M
0.00%
241.8M
+0.18%
241.4M
+89.98%
127.1M
N/A
Diluted Weighted Average Shares
241.8M
0.00%
241.8M
+0.18%
241.4M
+89.98%
127.1M
N/A
Balance Sheet
Cash and Cash Equivalents
N/A
N/A
157
+9.79%
143
-12.80%
164
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
0
-100.00%
157
+9.79%
143
-12.80%
164
N/A
Total Current Assets
N/A
N/A
9,025
+3.06%
8,757
-54.72%
19,338
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Assets
0
-100.00%
9,025
+3.06%
8,757
-54.72%
19,338
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
329,824
+36.09%
242,362
+60.68%
150,833
N/A
Total Current Liabilities
N/A
N/A
347,260
+33.03%
261,043
+55.24%
168,159
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
N/A
N/A
347,260
+33.03%
261,043
+55.24%
168,159
N/A
Retained Earnings
-3.4M
-8.93%
-3.8M
+2.32%
-3.7M
+4.18%
-3.6M
N/A
Total Stockholders Equity
268,815
+179.48%
-338,236
+34.07%
-252,286
+69.52%
-148,821
N/A
Total Shares Outstanding
241.8M
0.00%
241.8M
0.00%
241.8M
+0.18%
241.4M
N/A
Cash Flow
Cash from Operating Activities
-32,275
-63.09%
-87,448
-36.04%
-136,724
+69.58%
-80,627
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
32,118
-63.28%
87,462
-36.02%
136,702
+69.35%
80,722
N/A
Financials Ratio
Gross Margin
N/A
N/A
59.91%
+162.22%
22.85%
+64.41%
13.90%
N/A
Operating Margin
N/A
N/A
-37,863.44%
+1,474.27%
-2,405.15%
-49.00%
-4,715.69%
N/A
Return on Assets
7,495.53%
+875.37%
-966.71%
-8.64%
-1,058.11%
+86.18%
-568.32%
N/A
Return on Equity
-974.45%
-3,447.49%
29.11%
-60.72%
74.11%
-2.75%
76.21%
N/A
Revenue Growth
N/A
N/A
-96.33%
-140.68%
236.78%
N/A
N/A
N/A
Current Ratio
N/A
N/A
0.03
-22.39%
0.03
-70.87%
0.12
N/A
Cash Ratio
N/A
N/A
0.0005
0.00%
0.0005
-50.00%
0.001
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow